Osimertinib Incident

The development of tyrosine kinase inhibitors (TKIs) targeting mutant epidermal growth factor receptor (EGFR) proteins has pioneered the success of targeted therapy for non-small cell lung cancer (NSCLC). Osimertinib, a third-generation EGFR-TKI drug, is currently considered a first-line treatment for patients with NSCLC with sensitizing EGFR mutations, a second-line treatment for patients who develop a resistance-associated mutation T790M after prior EGFR-TKIs, and an adjuvant treatment for patients with early resected NSCLC with EGFR mutations.

Despite durable responses in patients with advanced NSCLC, resistance to osimertinib inevitably emerges, similar to other targeted therapies. Different resistance mechanisms develop when osimertinib is administered in the first-line versus second-line setting, demonstrating the importance of selective pressure and clonal evolution of tumor cells. Standard treatment after progression to osimertinib includes additional targeted therapies when targetable genetic alterations are detected, and cytotoxic chemotherapy with or without anti-angiogenic and immunotherapeutic agents.

OsimertinibThe original drug has been launched in China and has been covered by medical insurance. The price of 80mg*30 tablets per box may be around 5,000 yuan, which is relatively expensive. Currently available overseas Osimertinib generics, such as the specifications produced by Bangladesh Pharmaceutical FactoryThe price of each box of 80mg*30 tablets may be more than 800 yuan (the price may fluctuate due to exchange rate effects), which is relatively cheap. Osimertinib generics have basically the same pharmaceutical ingredients as the original drugs sold domestically and abroad. For more drug information and specific prices, please consult Yaode Medical Consultant.